Drilldown: Medicines
Medicines > classes 
:
Cathinone or
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism) or
dissociative
:
Cathinone or
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism) or
dissociative Use the filters below to narrow your results.
generic:
None (2) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
3-MMC (1) ·
4-MeO-PCP (1) ·
Butylone (1) ·
Cathinone (1) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Ephenidine (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Eticyclidine (1) ·
Hexedrone (1) ·
Ibogaine (1) ·
Mephedrone (1) ·
Methcathinone (1) ·
Methoxetamine (1) ·
Methylone (1) ·
Mexedrone (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
Pentedrone (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Xenon (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Contains salvinorin A (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent; active ingredient in khat (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3)
uses:
None (33) ·
Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
preparations:
fda max:
duration:
bioavailability:
pregnancy:
Showing below up to 35 results in range #1 to #35.